Akari Therapeutics to Present at the 2026 Biotech Showcase
MWN-AI** Summary
Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company specialized in oncology, is set to present at the 2026 Biotech Showcase on January 13, 2026, at 9:30 AM PT in San Francisco. Abizer Gaslightwala, the President and CEO, will outline the company’s innovative antibody drug conjugate (ADC) platform, strategic priorities, and key milestones for the coming year. This event, running from January 12-14, provides an opportunity for in-person meetings between Akari’s management and qualified investors.
Akari is at the forefront of developing ADCs with a unique payload known as PH1, which specifically targets RNA splicing. This platform enables the company to create ADC candidates optimized for various antigen targets. Their lead candidate, AKTX-101, specifically targets the Trop2 receptor found on cancer cells. Utilizing a proprietary linker, AKTX-101 allows the PH1 payload to effectively deliver its effects directly into tumors with minimal off-target consequences.
What sets PH1 apart is its function as a spliceosome modulator, disrupting RNA splicing processes in cancer cells. Preclinical studies indicate that AKTX-101 can induce cancer cell death while simultaneously activating both the innate and adaptive immune responses. It has demonstrated significant activity and extended survival in preclinical models compared to traditional ADCs. Moreover, AKTX-101 shows potential for synergistic effects when combined with checkpoint inhibitors, highlighting its dual-action capability both as a standalone treatment and in combination therapies.
Akari is moving forward with IND enabling studies for AKTX-101 with the objective of commencing First-In-Human trials by late 2026 or early 2027. Additionally, the company is progressing with AKTX-102, targeted at gastrointestinal and lung cancers. For more details, visit www.akaritx.com.
MWN-AI** Analysis
As Akari Therapeutics prepares for its presentation at the 2026 Biotech Showcase, investors should closely monitor several key aspects of the company and its product pipeline. The market potential for Akari is compelling, primarily due to its innovative approach to antibody drug conjugates (ADCs) and the unique payload it leverages—PH1, which modulates RNA splicing.
Akari’s lead candidate, AKTX-101, is positioned to attract investor attention, especially considering its promising preclinical data that suggests enhanced efficacy compared to traditional ADCs. Importantly, the ability of AKTX-101 to work synergistically with checkpoint inhibitors—and its demonstrated activity against key oncogenic drivers such as KRAS and BRAF—could place the drug at a competitive advantage in a crowded oncology market.
In reviewing the market landscape, Akari’s strategic priorities and milestones outlined for 2026 are essential. The initiation of IND enabling studies for AKTX-101, intending to start the First-In-Human trial by late 2026 or early 2027, marks a pivotal moment for the company. Investors should note that the transition from preclinical to clinical stages can significantly influence stock performance and investor sentiment.
Moreover, Akari's exploration of additional ADC candidates, such as AKTX-102, which targets novel areas in gastrointestinal and lung cancers, reflects a diversified approach to product development. This could enhance resilience against volatility in any single trial outcome.
Investors should also consider the management's availability for one-on-one meetings at the conference, facilitating deeper insights into strategic vision and potential future catalysts. Overall, while the biotech sector remains inherently risky, Akari Therapeutics presents a compelling opportunity for growth, especially as its innovative ADC platform approaches clinical validation. Keeping a watchful eye on upcoming developments will be crucial for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
In-person presentation on Tuesday, January 13th at 9:30 AM PT
As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026
TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA.
Presentation details are as follows:
Date/Time: Tuesday, January 13, 2026 at 9:30 AM PST
Location: Yosemite A (Ballroom Level)
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGF3, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ**
What are the key advancements in Akari Therapeutics Plc AKTX's ADC platform that will be highlighted during Mr. Gaslightwala's presentation at the 2026 Biotech Showcase?
Can you elaborate on the strategic priorities for Akari Therapeutics Plc AKTX leading up to 2026, especially concerning clinical trials and regulatory goals?
How does Akari Therapeutics Plc AKTX plan to differentiate its lead candidate, AKTX-101, from other antibody drug conjugates in the oncology market?
In light of the promising preclinical results, what are the expectations for AKTX-101's performance in the upcoming First-In-Human trial scheduled for late 2026/early 2027?
**MWN-AI FAQ is based on asking OpenAI questions about Akari Therapeutics Plc (NASDAQ: AKTX).
NASDAQ: AKTX
AKTX Trading
-16.48% G/L:
$0.2225 Last:
640,454 Volume:
$0.258 Open:
